🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. 4D-150 IVT

    4D Molecular Therapeutics

    Diabetic Macular Edema

    phase 2 mab active

    1 trial

  2. 4D-150 IVT

    4D Molecular Therapeutics

    Neovascular (Wet) Age-Related Macular Degeneration

    phase 2 mab active

    1 trial

  3. 4D-310

    4D Molecular Therapeutics

    Fabry Disease

    phase 2 mab active

    2 trials

  4. 4D-710

    4D Molecular Therapeutics

    Cystic Fibrosis Lung

    phase 2 mab active

    1 trial

  5. 5 mg Serlopitant Tablets

    VYNE Therapeutics

    Refractory Chronic Cough

    phase 2 small molecule completed

    1 trial

  6. 5 mg/kg CM-101

    Chemomab Therapeutics

    Nonalcoholic Steatohepatitis

    phase 2 mab completed

    1 trial

  7. 5% Bisphosphocin Topical Gel

    Lakewood-Amedex Biotherapeutics

    Chronic Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial

  8. 5% Nu-3 gel

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infection

    phase 2 small molecule active

    1 trial

  9. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  10. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial

  11. 60 mg Prednisone

    United Therapeutics Europe Ltd

    Airway Inflammation

    phase 2 small molecule completed

    1 trial

  12. 627

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  13. 68Ga-FAPI-46, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis, axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  14. 70 mL red beetroot juice

    United Therapeutics Europe Ltd

    Overweight

    phase 2 other active

    1 trial

  15. 75mg SHP647 (PF-00547659)

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  16. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Cancer

    phase 2 small molecule active

    1 trial

  17. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Cancer

    phase 2 small molecule active

    1 trial

  18. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Salivary Gland Carcinoma

    phase 2 small molecule terminated

    1 trial

  19. 9-ING-41

    ACTUATE THERAPEUTICS, INC.

    Pancreatic Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  20. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Bone Mineral Density

    phase 2 small molecule completed

    1 trial

  21. A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

    Sanofi-aventis Healthcare Pty Ltd

    Type 1 diabetes mellitus

    phase 2 other active

    1 trial

  22. A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress

    Seaport Therapeutics

    Major Depressive Disorder (MDD), with or without Anxious Distress

    phase 2 other active

    1 trial

  23. A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

    Merck Sharp and Dohme

    Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)

    phase 2 other active

    1 trial

  24. A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)

    Takeda

    Idiopathic Hypersomnia (IH)

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources